Biotech bites: Sirtex to be listed on S&P/ASX 200
Tuesday, 18 December, 2012
Anti-cancer company Sirtex Medical (ASX:SRX) has received a Christmas treat by being slated to be listed on the S&P/ASX 200 index.
This follows the removal of Integra Mining Limited (ASX:IGR) from the list by S&P Dow Jones Indices, pending approval of the merger of Integra with Silver Lake Resources (ASX:SLR).
Sirtex will join the S&P/ASX 200 after the close of trading on 24 December 2012, just as Santa is hefting his sack on to his sleigh.
Sirtex Medical specialises in SIR-Spheres microspheres, which are a medical device used to treat liver cancer by delivering Selective Internal Radiation Therapy (SIRT) to the liver.
Sales of SIR-Sphere have been growing, particularly in the United States and the Asia Pacific region.
The company's share price (ASX:SRX) jumped 5% during the day's trading, up 6c to $12.75. This time last year they were changing hands for $4.34.
Stevia leaf extract has potential as an anticancer treatment
When fermented with bacteria isolated from banana leaves, stevia extract kills off pancreatic...
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
How brain stem cells move between resting and active states
Understanding this process is crucial, because it underpins how the brain repairs itself and...
